Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02315 百奧賽圖-B
BIOCYTOGEN-B
Listing Date2022/09/01
Listing Price25.220
 
Quote
Subscription Result
  • Subscription Rate
    5.93x
  • Guarantee One Lot Size
    14 lot
  • One Lot Success Rate
    50%
COMPANY PROFILE

Biocytogen Pharmaceuticals (Beijing) founded in 2009, it is a biopharmaceutical and revenue-generating pre-clinical research services company. It has two Core Products, YH003 and YH001, and 10 other pipeline product candidates.

The Group’s Core Product YH003 is primarily being developed for pancreatic ductal adenocarcinoma, melanoma and other advanced solid tumors. Its other Core Product YH001 is primarily being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC) and other solid tumors. Most of its clinicalstage drug candidates, including both Core Products, are developed as combination therapies.

As of 13 Aug 2022, the Group had 258 registered trademarks, 93 registered patents and four software copyrights, and filed 283 patent applications in 17 countries or regions. It had two issued patents and 30 filed patent applications in relation to its Core Products.

BASIC INFORMATION
MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot500
GLOBAL OFFERING
No. of Offer Shares21.76M H shares
No. of International Offer Shares19.58M H shares
No. of HK Offer Shares2.18M H shares
Offer Price$25.22
Stock Code2315
Sponsor(s)Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited
Underwriter(s)Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, CMB International Capital Limited, CLSA Limited, BOCOM International Securities Limited, Futu Securities International (Hong Kong) Limited, Valuable Capital Limited, Haitong International Securities Company Limited
TIME TABLE
Application PeriodAug 19 (Fri) - noon, Aug 24 (Wed)
Price Determination DateAug 24 (Wed)
Result Announcement DateOn or before Aug 31 (Wed)
Result Announcement DateOn or before Aug 31 (Wed)
Dealings in Shares commence onSep 01, 2022. (Thu)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$25.22
Capitalization10.00B
NAV / share ($)$4.31 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 25.22, the net proceeds raised would be HKD 471.10M, of which
70% : Fund further clinical research and development of Core Products, YH003 and YH001
15% : Fund antibody drug discovery and development
10% : Fund pre-clinical and clinical development of other pipeline products
5% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
:
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2022 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.